Single-arm Study With Bimiralisib in Patients With HNSCC Harboring NOTCH1 Loss of Function Mutations
Status:
Completed
Trial end date:
2020-08-05
Target enrollment:
Participant gender:
Summary
Preclinical data and limited clinical evidence suggest that Head and Neck Squameous Cell
Carcinoma tumors harboring certain mutations may respond well to PI3K/mTOR inhibition
(phosphatidylinositol-3-kinase/ mammalian target of rapamycin inhibition).
The current study enrolls patients with refractory and / or metastatic Head and Neck
Squameous Cell Carcinoma based on the mutational status of their disease to assess the
response to treatment with bimiralisib, an orally available pan-PI3K/mTOR inhibitor
(phosphatidylinositol-3-kinase/ mammalian target of rapamycin inhibitor).